


## Pericyazine

## Chemical Properties

CAS No. :	2622-26-6
Formula:	C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>5</sub>
Molecular Weight:	365.49
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Pericyazine (Propericiazine) is a selective D <sub>2</sub> -dopamine receptor antagonist. Pericyazine is a first-generation antipsychotic drug that is used as an adjunct to the short-term management of severe anxiety states and psychosis.
Targets(IC <sub>50</sub> )	Dopamine Receptor

## Solubility Information

Solubility	DMSO: 83.33 mg/mL (228 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: $< 8.33$ mg/mL (22.79 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.33 mg/mL (22.79 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7361 mL	13.6803 mL	27.3605 mL
5 mM	0.5472 mL	2.7361 mL	5.4721 mL
10 mM	0.2736 mL	1.368 mL	2.7361 mL
50 mM	0.0547 mL	0.2736 mL	0.5472 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. *Subst Abuse Rehabil.* 2012 May 28;3:43-7.

Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. *Psychopharmacology (Berl).* 1989;99 Suppl:528-31.

Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. *Biomed Res Int.* 2014;2014:656370.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481